Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 142 participants.
Also called NCT01596504
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 142 participants
- Sponsor
- Registry
-
NCT01596504 -
2012-000027-40
-
- Main results
- Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Germany
- Registry status
- Completed
Technical summary
Registry record NCT01596504. Randomized; no masking; primary purpose treatment. Start 2012-05 (registry gives no type); primary completion 2013-07 (actual). Results posted on 2016-10-14.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Lixisenatide (AVE0010)
- Intervention (Drug)
- Liraglutide
- Intervention (Drug)
- Insulin Glargine
- Intervention (Drug)
- Metformin
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct01596504- Content hash
f911417e7635f0ec1b89938a3172500e809200f85138a4101ad0cabfcb909040